Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR3 | P49682 | 14/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5136872 | 0.94 | LMNA (0.40) | CXCR3LMNAMEN1POLBKMT2A | |
| SCHEMBL5135244 | 0.91 | KDM4E (0.35) | CXCR3LMNAMEN1POLBKMT2A | |
| SCHEMBL650145 | 0.87 | LPAR1 (0.40) | MEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL5135309 | 0.86 | TLR7 (0.41) | — | |
| SCHEMBL5135388 | 0.86 | CXCR3 (0.38) | CXCR3LMNAMEN1POLBKMT2A | |
| SCHEMBL5136929 | 0.86 | LTB4R2 (0.37) | LMNAMEN1POLBKMT2ATDP1 | |
| SCHEMBL5071417 | 0.82 | TSHR (0.39) | LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL5137622 | 0.82 | CXCR3 (0.44) | CXCR3 | |
| SCHEMBL5135939 | 0.82 | HSP90AA1 (0.38) | — | |
| SCHEMBL5136262 | 0.81 | TLR7 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1490044-A4 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORP (US) | 2008-04-16 | — | — | EP | disclosed |
| EP-1490044-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORPORATION (US) | 2004-12-29 | — | — | EP | disclosed |
| WO-2003084524-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORPORATION (US) | 2003-10-16 | — | — | WO | disclosed |